Table 1.

Recent clinical trials.

MDM2 Inhibitors
Compound	Indication	Phase	Clinical Trial Identifier
RG7112	Hematological neoplasms	I	NCT00623870
	Acute Myeloid Leukemia	Ib/II	NCT03850535
RG7388	Acute Myeloid Leukemia	III	NCT02545283
	Solid Tumors	I	NCT00559533
	Multiple Myeloma	I/II	NCT02633059
	Follicular Lymphoma and Large B-Cell Lymphoma	Ib/II	NCT03135262
	Non-Hodgkin’s Lymphoma	I/II	NCT02624986
	Acute Myeloid Leukemia	I	NCT02670044
	Breast Cancer (Stage IV, Estrogen Receptor +)	I/II	NCT03566485
MK-8242	Acute Myeloid Leukemia	I	NCT01451437
	Solid Tumors	I	NCT01463696
AMG-232	Solid Tumors or Multiple Myeloma	I	NCT01723020
	Acute Myeloid Leukemia	I	NCT02016729
	Metastatic Melanoma	Ib/IIa	NCT02110355
	Multiple Myeloma	I	NCT03031730
	Soft Tissue Sarcoma	Ib	NCT03217266
	Acute Myeloid Leukemia	Ib	NCT04190550
MDM2/MDMX Inhibitor
ALRN-6924	Hematological neoplasms and Small Tumors	I	NCT03654716
	Metastatic Solid Tumors	I	NCT03725436
	Solid Tumors or Lymphoma	I/IIa	NCT02264613
Mutant p53 Reactivators
APR-246	Acute Myeloid Leukemia or Myelodysplastic Syndromes	II	NCT03931291
	Myeloid Malignancy	I	NCT04214860
	Solid Tumors	I/II	NCT04383938
	Esophageal Cancer	Ib/II	NCT02999893
	Non-Hodgkin’s Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia	I/II	NCT04419389
	Myeloid Malignancy	Ib/II	NCT03588078
	Myelodysplastic Syndromes	III	NCT03745716
	High Grade Serous Ovarian Cancer	II	NCT03268382
	Melanoma (BRAF/V600)	Ib/II	NCT03391050
	Myeloid Malignancy	Ib/II	NCT03072043
	High Grade Serous Ovarian Cancer	Ib/II	NCT02098343
	Hematological neoplasms and Prostate Cancer	I	NCT00900614
Ganetespib	Metastatic Ovarian Cancer (Mutant p53)	I/II	NCT02012192
SAHA	Advanced Cancer (Mutant p53)	I	NCT02042989
	Metastatic Melanoma	II	NCT00121225
	Advanced Cancer	I	NCT00324480
p53 Gene Therapy
Ad-p53 + Immune Checkpoint Inhibitor	Solid Tumors or Lymphoma	II	NCT03544723
	Head and Neck Cancer or Metastatic Solid Tumors	I/II	NCT02842125